Maze Therapeutics has announced the completion of a $115 million Series D financing round to further the development of its precision medicine pipeline targeting renal, cardiovascular, and metabolic diseases. The funding, co-led by Frazier Life Sciences and Deep Track Capital, will primarily support the advancement of two lead programs: MZE829, an oral APOL1 inhibitor, and MZE782, an oral SCL6A19 inhibitor.
MZE829 for APOL1 Kidney Disease
MZE829 is being developed as a treatment for APOL1 kidney disease (AKD), a genetically defined form of kidney disease that disproportionately affects individuals of African descent. AKD includes conditions such as focal segmental glomerulosclerosis (FSGS). A Phase 2 clinical trial is anticipated to begin in the first quarter of 2025 to evaluate the efficacy and safety of MZE829 in patients with AKD and FSGS.
"Maze has two significant opportunities with MZE829 and MZE782 to disrupt the treatment landscape for people with kidney disease who have had to rely on disease management rather than altering the course of disease with a modifying therapy," said Rebecca Luse, Principal of Deep Track Capital.
MZE782 for Chronic Kidney Disease and Phenylketonuria
MZE782 is currently undergoing a Phase 1 healthy volunteer trial. Maze Therapeutics is exploring its potential as a treatment for chronic kidney disease (CKD) and phenylketonuria (PKU). Data from the Phase 1 trial is expected in the second half of 2025, which will inform further development plans for MZE782 in these indications.
Precision Medicine Approach
Maze Therapeutics is leveraging human genetics to develop novel, small-molecule precision medicines. Their approach involves identifying genetic variants that drive disease and developing targeted therapies to address these underlying causes. This strategy aims to provide more effective and personalized treatments for patients with complex diseases.
"We are grateful and honored to have had the continued support of our long-term investors over the past several years and are thrilled to welcome the Frazier, Deep Track, Janus and Logos teams as we advance our two lead clinical programs, MZE829 and MZE782, and continue to leverage our Compass Platform," said Jason Coloma, Ph.D., chief executive officer of Maze.
